Weight Loss During Neoadjuvant Chemotherapy Increases Postoperative Complications in Pancreatic Cancer Resection Sahil Doshi BS¹, Amy Wells MS^{1,2}, John Abad MD^{1,2} Akhil Chawla MD^{1,2,3}

¹Division of Surgical Oncology, Department of Surgery, Northwestern Medicine Regional Medical Group ²Northwestern University Feinberg School of Medicine ³Robert H. Lurie Comprehensive Cancer Center

Characte

male

moker

Diabete

Amer

Asian

Black

Unkno

White

ispanic

No

Yes

listory

Hyperter ¹Median ²Wilcoxo

Race

Background

- Neoadjuvant chemotherapy (NAC) is a standard preoperative treatment for localized pancreatic cancer.
- Preoperative weight loss has been shown to increase postoperative complications for complex surgery in the literature.
- However, the specific effects of NAC-associated weight loss on postoperative complications have not been extensively studied.

Research Objectives

- To understand NAC practice patterns and its correlation with NAC-associated weight loss.
- To evaluate effects of weight loss during NAC on postoperative complications in patients who underwent pancreatectomy for pancreatic cancer.
- To determine if weight loss is an independent predictor of a postoperative complication.

Methods

- The National Surgical Quality Improvement Program (NSQIP) database was used from 2014 to 2019.
- Patients who were diagnosed with pancreatic adenocarcinoma (PDAC) and received NAC were included in the analysis.
- Preoperative weight loss was defined as >10% weight loss in the six months prior to surgery in patients undergoing NAC.
- Fisher's exact test and Pearson's chi-squared test were applied to establish significance between variables, and logistic regression was used to identify independent predictors of a postoperative complication.

M Northwestern Medicine Feinberg School of Medicine

Figure 1. Population Derivation




Table 1. Demographic Characteristics

eristic	No Weight Loss, N = 4,677 ¹	Weight Loss, N = 913 ¹	p-value ²						
	66 (59 <i>,</i> 72)	66 (60 <i>,</i> 72)	0.14						
			0.009						
2	2,253 (48%)	483 (53%)							
	2,424 (52%)	430 (47%)							
	784 (17%)	207 (23%)	<0.001						
;	1,411 (30%)	341 (37%)	<0.001						
			0.058						
can Indian or Alaska Native	9 (0.2%)	4 (0.4%)							
	152 (3.2%)	23 (2.5%)							
or African American	385 (8.2%)	71 (7.8%)							
Hawaiian or Pacific Islander	3 (<0.1%)	0 (0%)							
wn/Not Reported	368 (7.9%)	51 (5.6%)							
	3,760 (80%)	764 (84%)							
Ethnicity			0.007						
	4,203 (90%)	845 (93%)							
wn	306 (6.5%)	35 (3.8%)							
	168 (3.6%)	33 (3.6%)							
of COPD	155 (3.3%)	41 (4.5%)	0.077						
nsive Medication Use	2,289 (49%)	459 (50%)	0.5						
(IQR); n (%)									
on rank sum test; Pearson's Chi-squared test; Fisher's exact test									

Figure 2. NAC Trends Weight_Loss

Table 2. Postoperative Complication Rates

Operation Y

haracteristic	No Weight Loss, N = 4,677 ¹	Weight Loss, N = 913 ¹	p-value ²
rgan/Space SSI			>0.9
No Complication	4,200 (90%)	820 (90%)	
Organ/Space SSI	477 (10%)	93 (10%)	
/ound Disruption	, ,	. ,	0.038
No Complication	4,628 (99%)	910 (100%)	
Wound Disruption	49 (1.0%)	3 (0.3%)	
neumonia	, , ,		0.064
No Complication	4,563 (98%)	881 (96%)	
Pneumonia	114 (2.4%)	32 (3.5%)	
nplanned Reintubation			0.004
No Complication	4,573 (98%)	878 (96%)	
Unplanned Intubation	104 (2.2%)	35 (3.8%)	
ulmonary Embolism	101 (2.270)	33 (3.570)	0.4
No Complication	4,633 (99%)	907 (99%)	0.4
Pulmonary Embolism	44 (0.9%)	6 (0.7%)	
entilator >48 Hours	(0.5%)	0 (0.770)	<0.001
No Complication	1 505 (00%)	870 (06%)	<0.001
•	4,595 (98%)	879 (96%)	
On Ventilator greater than 48 Hours	82 (1.8%)	34 (3.7%)	0.010
rogressive Renal Insufficiency	4 ((7)/4000()	000 (000)	0.013
No Complication	4,667 (100%)	906 (99%)	
Progressive Renal Insufficiency	10 (0.2%)	7 (0.8%)	
rinary Tract Infection			0.044
No Complication	4,571 (98%)	882 (97%)	
Urinary Tract Infection	106 (2.3%)	31 (3.4%)	
VA/Stroke with Neurological Deficit			0.2
No Complication	4,670 (100%)	910 (100%)	
Stroke/CVA	7 (0.1%)	3 (0.3%)	
ardiac Arrest Requiring CPR			0.055
Cardiac Arrest Requiring CPR	40 (0.9%)	14 (1.5%)	
No Complication	4,637 (99%)	899 (98%)	
30 Days from Operation to Death	58 (1.2%)	14 (1.5%)	0.5
epsis			0.068
No Complication	4,343 (93%)	832 (91%)	
Sepsis	334 (7.1%)	81 (8.9%)	
eptic Shock		,,	< 0.001
No Complication	4,592 (98%)	877 (96%)	
Septic Shock	85 (1.8%)	36 (3.9%)	
eoperation	203 (4.3%)	55 (6.0%)	0.027
ancreatic Fistula	200 (4.070)	33 (0.070)	0.027
Biochemical Leak only	64 (1.4%)	9 (1.0%)	0.4
No	4,190 (90%)	833 (91%)	
Unknown	4,190 (90%) 24 (0.5%)	6 (0.7%)	
	. ,	. ,	
Yes	399 (8.5%)	65 (7.1%)	0.000
ancreatic Drain	4,127 (88%)	833 (91%)	0.009
elayed Gastric Emptying			0.2
No	4,120 (88%)	785 (86%)	
Unknown	18 (0.4%)	4 (0.4%)	
Yes-no oral intake by POD 14	51 (1.1%)	15 (1.6%)	
Yes-tube to external drainage/NG tube present/reinserted	488 (10%)	109 (12%)	
ercutaneous Drain	407 (8.7%)	81 (8.9%)	0.9
rain Still Present 30 Days After Operation	. ,	55 (6.0%)	0.7
	265 (5.7%)	55 (0.070)	0.7

²Pearson's Chi-squared test; Fisher's exact test

		Univariate Analysis		Multivariate Analysis		lysis		Univariate Analysis			-	Multivariate Analysis			
aracteristic	Ν	exp(Beta)	95% Cl ¹	p- value	OR1	95% Cl ¹	p-value	Hispanic Ethnicity	5,590						
ight Loss	5,590							No		_	-		_	_	
No		-	-		—	-		Unknown			1.00,				
Yes		1.03	1.00, 1.07	0.053	1.17	1.01, 1.36	0.031			1.06	1.12	0.034			
2	5,590	1.00	1.00, 1.00	0.2				Yes		1.05	0.98 <i>,</i> 1.12	0.2			
:	5,590							History of COPD	5,590						
female		—	—		—	—		No							
male		1.06	1.03, 1.08	<0.00 1	1.26	1.13, 1.40	<0.001	Yes		-	 1.02,		-		
oker	5,590									1.09	1.17	0.012	1.38	1.83	0.030
No		_	-		_	_		Hypertensive Medication	5 500						
Yes		1.01	0.98, 1.04	0.5				Use No	5,590						
betes	5,590		1.01							-	-		—	-	
No	-,	-	-		-	-		Yes		1.05	1.02, 1.07	<0.00 1	1.20	1.08, 1.34	<0.00 1
Insulin		0.99	0.96, 1.02	0.6				Pancreatic Duct Size	5,590		1.07	-		1.51	-
Non-Insulin		1.03	0.99, 1.07	0.10				<3 mm		_	-		_	-	
ce in the second se	5,590							>=3 mm		0.06	0.93,	0.022	0.99	0.76,	0.11
American Indian or Alaska Native		_	_		-	_		Unknown		0.96	1.00 0.92,	0.032	0.88	1.03 0.67,	
Asian		0.80	0.61,	0.11						0.95	0.99	0.011	0.80	0.95	0.013
			1.05					Pancreatic Gland Texture	5,590						
Black or African American		0.83	0.63, 1.08	0.2				Non-Soft		_	_		_	_	
Native Hawaiian or Pacific Islander		0.75	0.41, 1.39	0.4				Soft		1.06	1.03,	< 0.00	1.28	1.10 <i>,</i> 1.49	0.001
Unknown/Not Reported		0.88	0.67, 1.15	0.3				Unknown		1.02	1.10 0.99,	1 0.3	1.18	1.01,	0.032
White		0.79	0.61,	0.083				¹ Cl = Confidence Interval, OR =	Odds Ratio		1.05			1.37	

Table 3. Regression Analysis

Results

- Of the 17,735 patients diagnosed with PDAC, 5,590 received NAC. Of this subpopulation of NAC recipients, 913 experienced preoperative weight loss (Figure 1).
- The percentage of individuals who experienced weight loss from NAC has stayed stable from 2014 to 2019, but the percentage of individuals who experienced weight loss and a postoperative complication has slightly declined in the same time frame (Figure 2).
- NAC patients who experienced weight loss were most often female and were more likely to be smokers and have a diagnosis of diabetes. Of note, there was no statistically significant difference in age between the two groups (Table 1).
- NAC-associated weight loss was associated with a higher rate of severe complications such as unplanned intubation (3.8% vs. 2.2%), ventilator use for >48 hours (3.7% vs. 1.8%), and septic shock (3.9% vs. 1.8%) **(Table 2)**.
- NAC-associated weight loss, sex, history of COPD, hypertensive medication use, and pancreatic gland texture were independent predictors of a postoperative complication (Table 3)

Conclusions

- Despite the increasing use of multi-agent NAC regimens over the past several years, NAC-associated weight loss has not increased and management of those who do experience weight loss has improved.
- NAC patients who experienced significant weight loss experienced twice the rate of severe postoperative complications including prolonged ventilator use and septic shock.
 - The use of prehabilitation during NAC may prevent significant weight loss, thus decreasing rates of severe complications after pancreatectomy.